{
    "data": [
        {
            "news_url": "https://seekingalpha.com/article/4680296-2-more-potential-biotech-buyout-targets",
            "image_url": "https://cdn.snapi.dev/images/v1/t/h/image-1403479106-2340410.jpg",
            "title": "2 More Potential Biotech Buyout Targets",
            "text": "M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.",
            "source_name": "Seeking Alpha",
            "date": "Mon, 25 Mar 2024 13:07:32 -0400",
            "topics": [
                "manda",
                "paylimitwall"
            ],
            "sentiment": "Positive",
            "type": "Article",
            "tickers": [
                "AZN",
                "BAYRY",
                "BCYC",
                "BMY",
                "EXEL",
                "FUSN",
                "IPSEY",
                "LLY",
                "MRK",
                "NVS",
                "TAK"
            ]
        },
        {
            "news_url": "https://www.zacks.com/stock/news/2244951/merck-s-mrk-keytruda-lynparza-combo-fails-2nd-lung-cancer-study?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_-_medical_sector-2244951",
            "image_url": "https://cdn.snapi.dev/images/v1/1/v/472-2337731.jpg",
            "title": "Merck's (MRK) Keytruda-Lynparza Combo Fails 2nd Lung Cancer Study",
            "text": "Merck's attempt to use the Keytruda-Lynparza combination in certain non-small cell lung cancer patients has come up short with a second pivotal study failure.",
            "source_name": "Zacks Investment Research",
            "date": "Fri, 22 Mar 2024 11:31:11 -0400",
            "topics": [],
            "sentiment": "Negative",
            "type": "Article",
            "tickers": [
                "MRK"
            ]
        },
        {
            "news_url": "https://www.fool.com/investing/2024/03/21/bull-market-and-beyond-2-stocks-to-buy-and-hold/",
            "image_url": "https://cdn.snapi.dev/images/v1/u/r/urlhttps3a2f2fgfoolcdncom2fedi-2335348.jpg",
            "title": "Bull Market and Beyond: 2 Stocks to Buy and Hold Forever",
            "text": "Medtronic and Merck are innovative healthcare leaders. Both are developing new products to keep sales growing.",
            "source_name": "The Motley Fool",
            "date": "Thu, 21 Mar 2024 09:45:00 -0400",
            "topics": [
                "StocksToWatch"
            ],
            "sentiment": "Positive",
            "type": "Article",
            "tickers": [
                "MDT",
                "MRK"
            ]
        }
    ],
    "total_pages": 1108
}